Schneider National outlines EPS guidance of $0.70 to $1 for 2026 with $40 million in new cost savings and executive transition amid industry supply attrition
Source link
China’s CSPC Pharmaceutical, AstraZeneca’s long-acting obesity drug partner
China’s CSPC Pharmaceutical, AstraZeneca’s long-acting obesity drug partner Source link






